SignalFDA/Bio

PVX-001: open-source Covid-19 vaccine starts Phase 1 trial

Open-source Covid-19 vaccine entering Phase 1 trial signals early clinical catalyst.

Context

What happened: PopVax said the first two participants received doses of PVX-001, its broadly protective COVID-19 vaccine candidate, in a Phase 1 trial in Melbourne, Australia, with enrollment of 36 healthy adults planned. Key numbers: First doses given 31 August 2026. Why it matters: The company says safety and immunogenicity data from its mRNA-LNP platform will help move preclinical programs, including rabies, HCV, TB, and Strep A candidates, into clinical trials over the next 2 years. PVX-001 will be made open-source after Phase 1.

What changed

PopVax said the first two participants received doses of PVX-001, its broadly protective COVID-19 vaccine candidate, in a Phase 1 trial in Melbourne, Australia, with enrollment of 36 healthy adults planned.

Why it matters

The company says safety and immunogenicity data from its mRNA-LNP platform will help move preclinical programs, including rabies, HCV, TB, and Strep A candidates, into clinical trials over the next 2 years. PVX-001 will be made open-source after Phase 1.

Sources